ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 133 citations in OpenAlex.
- Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.JCO precision oncology · 2021Trial
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.Targeted oncology · 2026Review
- FGFR1 Suppresses STING-Mediated Interferon Response in Endocrine Therapy-Resistant Breast Cancer.Cancer research communications · 2026Article
- Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragments.Communications medicine · 2026Article
- CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.The Journal of clinical investigation · 2026Article
- Article
- Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations.NPJ precision oncology · 2025Article
- Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer.bioRxiv : the preprint server for biology · 2025Article
- Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- ARID1A-Deficient and 11q13-Amplified Metastatic Pancreatic Cancer Initially Presenting as Retroperitoneal Fibrosis in a Patient with Familial CHEK2 Variant.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role.Breast cancer research and treatment · 2025Article
- Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.Cancer letters · 2025Article
- Article
- FGFR1 overexpression promotes resistance to PI3K inhibitor alpelisib in luminal breast cancer cells through receptor tyrosine kinase signaling-mediated activation of the estrogen receptor.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Advances in the role of membrane-bound transcription factors in carcinogenesis and therapy.Discover oncology · 2024Review
- Targeting FGFR for cancer therapy.Journal of hematology & oncology · 2024Review
- Systems Genome: Coordinated Gene Activity Networks, Recurring Coordination Modules, and Genome Homeostasis in Developing Neurons.International journal of molecular sciences · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 4 institutions in 3 countries.
Luigi FormisanoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Kimberly M StaufferDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Christian D YoungDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Neil E BholaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Angel L Guerrero-ZotanoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Valerie M JansenDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Mónica M EstradaBreast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Katherine E HutchinsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Jennifer M GiltnaneDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Luis J SchwarzDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Yao LuDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Justin M BalkoDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Olivier DeasXenTech, Evry, France.
Stefano CairoXenTech, Evry, France.
Jean-Gabriel JuddeXenTech, Evry, France.
Ingrid A MayerDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Melinda SandersDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Teresa C DuggerDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Roberto BiancoDepartment of Clinical Medicine, University of Naples Federico II, Naples, Italy.
Thomas StrickerDepartment of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@vanderbilt.edu thomas.stricker@vanderbilt.edu.
Carlos L ArteagaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@vanderbilt.edu thomas.stricker@vanderbilt.edu.
Vanderbilt University Medical Center · USFederico II University Hospital · ITUniversité d'Évry Val-d'Essonne · FRUniversity of Ferrara · IT
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MHigh-throughput Analysis of Mutations Identified by RNA-sequencing Triple NegativK08CA148912 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STRICKER, THOMAS PAUL · 2012 to 2016
$765kDusp4 in breast cancer: tumor suppressor biology and therapeutic strategiesR00CA181491 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BALKO, JUSTIN M · 2015 to 2017
$750kNCI NIH HHS K08 CA148912NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA098131NCI NIH HHS R00 CA181491
Abstract
PubMed holds no abstract for this paper.
Indexed as
Transcription, GeneticAnimalsBreast NeoplasmsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmEstrogen Receptor alphaEstrogen Receptor ModulatorsFemaleFibroblast Growth FactorsGene AmplificationGene Expression Regulation, NeoplasticHumansMiceMolecular Targeted TherapyNeoplasm StagingEstrogen Receptor alphaEstrogen Receptor ModulatorsFGFR1 protein, humanFibroblast Growth FactorsProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.